Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InspireMD, Inc.NSPR · Entity 7318 | Director | September 21, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InspireMD, Inc.
Report date September 21, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series J Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 | IndirectSee Footnote | 43,750 |
Reported balance
After 2026-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-18 · Other · Disposed 43,750 · Balance 43,750 F1: See Exhibit 99.1; Note 1 F2: See Exhibit 99.1; Note 2 F3: See Exhibit 99.1; Note 3 |
| Series J Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 | IndirectSee Footnote | 43,750 |
Reported balance
After 2026-09-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-18 · Other · Acquired 43,750 · Balance 43,750 F1: See Exhibit 99.1; Note 1 F4: See Exhibit 99.1; Note 4 F3: See Exhibit 99.1; Note 3 |
| Series K Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 | IndirectSee Footnote | 0 |
Reported balance
After 2026-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-18 · Other · Disposed 87,500 · Balance 0 F5: See Exhibit 99.1; Note 5 F6: See Exhibit 99.1; Note 6 F3: See Exhibit 99.1; Note 3 |
| Series K Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 | IndirectSee Footnote | 43,750 |
Reported balance
After 2026-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-18 · Other · Acquired 87,500 · Balance 43,750 F5: See Exhibit 99.1; Note 5 F7: See Exhibit 99.1; Note 7 F3: See Exhibit 99.1; Note 3 |
Filing footnotes · ownership attribution and instrument terms
F1: See Exhibit 99.1; Note 1
F2: See Exhibit 99.1; Note 2
F3: See Exhibit 99.1; Note 3
F4: See Exhibit 99.1; Note 4
F5: See Exhibit 99.1; Note 5
F6: See Exhibit 99.1; Note 6
F7: See Exhibit 99.1; Note 7
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 23, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherSeries K Warrant (right to buy) · Derivative | 87,500 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001493152-26-043910 · ownership.xml · derivative · entry 4 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 43,750 Underlying: Common Stock · 87,500 shares Expires not disclosed F5 · kind: See Exhibit 99.1; Note 5 F7 · derivative.expiration_date: See Exhibit 99.1; Note 7 F3 · ownership.direct: See Exhibit 99.1; Note 3 Read SEC document |
| September 18, 2026 Filed Sep 23, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherSeries K Warrant (right to buy) · Derivative | 87,500 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-26-043910 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires not disclosed F5 · kind: See Exhibit 99.1; Note 5 F6 · derivative.expiration_date: See Exhibit 99.1; Note 6 F3 · ownership.direct: See Exhibit 99.1; Note 3 Read SEC document |
| September 18, 2026 Filed Sep 23, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherSeries J Warrant (right to buy) · Derivative | 43,750 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001493152-26-043910 · ownership.xml · derivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires not disclosed F1 · kind: See Exhibit 99.1; Note 1 F4 · derivative.expiration_date: See Exhibit 99.1; Note 4 F3 · ownership.direct: See Exhibit 99.1; Note 3 Read SEC document |
| September 18, 2026 Filed Sep 23, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherSeries J Warrant (right to buy) · Derivative | 43,750 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-26-043910 · ownership.xml · derivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires not disclosed F1 · kind: See Exhibit 99.1; Note 1 F2 · derivative.expiration_date: See Exhibit 99.1; Note 2 F3 · ownership.direct: See Exhibit 99.1; Note 3 Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 20,000 | $0.88 | $17,500.00 |
DisclosureSEC source: 0001493152-26-026348 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,871 F1 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $0.87 to $0.88. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 5,000 | $1.15 | $5,750.00 |
DisclosureSEC source: 0001493152-26-023727 · ownership.xml · nonDerivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,871 Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 10,000 | $1.16 | $11,575.00 |
DisclosureSEC source: 0001493152-26-023727 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,871 F1 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.1550 to $1.1599. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 11, 2026 Filed May 12, 2026 23:35 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 10,000 | $1.19 | $11,900.00 |
DisclosureSEC source: 0001493152-26-022564 · ownership.xml · nonDerivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 632,871 F4 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.17 to $1.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:47 UTC Amendment | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 10,000 | $1.19 | $11,900.00 |
DisclosureSEC source: 0001493152-26-022763 · ownership.xml · nonDerivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,871 F6 · security: This Form 4/A is being filed solely to reflect that the reported transactions were not effected pursuant to a Rule 10b5-1(c) trading plan. The Form 4 filed on May 12, 2026 (the "Original Filing") inadvertently checked the box that the transactions were effected pursuant to a Rule 10b5-1(c) trading plan. The Reporting Person does not currently maintain any Rule 10b5-1 trading plans. The transaction details otherwise reported in the Original Filing remain accurate and unchanged. F4 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.17 to $1.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 08, 2026 Filed May 12, 2026 23:35 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 65,626 | $1.16 | $76,126.16 |
DisclosureSEC source: 0001493152-26-022564 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 622,871 F1 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.15 to $1.16. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F2 · balance_after: The Form 4 filed on August 1, 2025 (the "Original Filing") (and subsequent Form 4s reflecting this information) inadvertently reported that 20,661 shares of common stock purchased on July 30, 2025 were indirectly held by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris"). However, such shares were held directly by the Reporting Person. After adjusting for the foregoing and further technical adjustments, the Reporting Person (i) directly beneficially owned 557,245 shares of Common Stock and (ii) indirectly, through Osiris, beneficially owned 423,704 shares of Common Stock, in each case immediately prior to the transaction reported herein. F3 · balance_after: This Form 4 reflects the Reporting Person's correct beneficial ownership following the transaction reported herein. No change in the Reporting Person's pecuniary interest resulted from these corrections. Read SEC document |
| May 08, 2026 Filed May 13, 2026 20:47 UTC Amendment | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 65,626 | $1.16 | $76,126.16 |
DisclosureSEC source: 0001493152-26-022763 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,871 F6 · security: This Form 4/A is being filed solely to reflect that the reported transactions were not effected pursuant to a Rule 10b5-1(c) trading plan. The Form 4 filed on May 12, 2026 (the "Original Filing") inadvertently checked the box that the transactions were effected pursuant to a Rule 10b5-1(c) trading plan. The Reporting Person does not currently maintain any Rule 10b5-1 trading plans. The transaction details otherwise reported in the Original Filing remain accurate and unchanged. F1 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.15 to $1.16. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F2 · balance_after: The Form 4 filed on August 1, 2025 (and subsequent Form 4s reflecting this information) inadvertently reported that 20,661 shares of common stock purchased on July 30, 2025 were indirectly held by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris"). However, such shares were held directly by the Reporting Person. After adjusting for the foregoing and further technical adjustments, the Reporting Person (i) directly beneficially owned 557,245 shares of Common Stock and (ii) indirectly, through Osiris, beneficially owned 423,704 shares of Common Stock, in each case immediately prior to the transaction reported herein. F3 · balance_after: This Form 4 reflects the Reporting Person's correct beneficial ownership following the transaction reported herein. No change in the Reporting Person's pecuniary interest resulted from these corrections. Read SEC document |
| May 07, 2026 Filed May 8, 2026 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 6,378 | $1.15 | $7,334.70 |
DisclosureSEC source: 0001493152-26-022016 · ownership.xml · nonDerivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,599 F1 · price: The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.14 to $1.15. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 8, 2026 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 1,517 | $1.12 | $1,699.04 |
DisclosureSEC source: 0001493152-26-022016 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,221 Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 23:11 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 132,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002669 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,704 F1 · shares: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 5,073 | $1.81 | $9,182.13 |
DisclosureSEC source: 0001493152-25-027239 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,628 F1 · price: The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 09, 2025 Filed Feb 23, 2026 21:05 UTC Amendment | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 2,710 | $1.81 | $4,905.10 |
DisclosureSEC source: 0001493152-26-007752 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,628 F1 · shares: This Form 4/A amends the Form 4 filed on December 11, 2025 solely to correct the number of shares reported in Table I, Column 4. The number of shares reported in Column 5 was correct as originally filed. No other changes have been made. F2 · price: The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 5,073 | $1.86 | $9,435.78 |
DisclosureSEC source: 0001493152-25-026629 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,918 Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 10,130 | $1.85 | $18,740.50 |
DisclosureSEC source: 0001493152-25-026356 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,845 Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 13,431 | $1.62 | $21,758.22 |
DisclosureSEC source: 0001493152-25-022284 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,715 Read SEC document |
| July 30, 2025 Filed Aug 1, 2025 21:00 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 20,661 | $2.42 | $49,999.62 |
DisclosureSEC source: 0001641172-25-021930 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 444,195 F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on July 30, 2025 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement"). F2 · price: The purchase price per share of common stock in the Private Placement was $2.42. F3 · ownership.direct: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| July 01, 2025 Filed Jul 23, 2025 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherSeries I Warrant (right to buy) · Derivative | 87,500 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001641172-25-020693 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2025-07-23 F1 · ownership.direct: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| July 01, 2025 Filed Jul 23, 2025 20:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherCommon Stock | 87,500 | $1.38 | $120,986.25 |
DisclosureSEC source: 0001641172-25-020693 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 423,534 F1 · ownership.direct: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 22,254 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001493152-25-001732 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,129 Underlying: Common Stock · 22,254 shares Expires 2035-01-07 F3 · derivative.exercise_date: The options vest and become exercisable on the One Year Grant Anniversary Date, subject to the Reporting Person's continued service. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 48,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-001732 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,284 F1 · shares: These shares of common stock represent shares of restricted stock that shall vest on January 7, 2026 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:50 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherSeries H Warrant (right to buy) · Derivative | 87,500 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-24-023222 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2024-06-26 F1 · ownership.direct: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:50 UTC | InspireMD, Inc. NSPR · Entity 7318 | OtherCommon Stock | 87,500 | $1.38 | $120,986.25 |
DisclosureSEC source: 0001493152-24-023222 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 336,034 F1 · ownership.direct: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:52 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 16,647 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001493152-24-003776 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,875 Underlying: Common Stock · 16,647 shares Expires 2034-01-23 F3 · derivative.exercise_date: The options vest and become exercisable on the One Year Grant Anniversary Date, subject to the Reporting Person's continued service. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:52 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 43,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-003776 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,548 F1 · shares: These shares of common stock represent shares of restricted stock that shall vest on January 23, 2025 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:15 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 75,220 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001493152-23-018326 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,228 Underlying: Common Stock · 75,220 shares Expires 2033-05-17 F3 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:15 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 225,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-018326 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,000 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseSeries K Warrants to purchase Common Stock · Derivative | 87,500 | $1.63 Strike: $1.38 | $142,861.25 |
DisclosureSEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 6 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires not disclosed F10 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series K Warrants that were acquired in the Private Placement. F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. F11 · derivative.expiration_date: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin. F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseSeries J Warrants to purchase Common Stock · Derivative | 87,500 | $1.63 Strike: $1.38 | $142,861.25 |
DisclosureSEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 5 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires not disclosed F8 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series J Warrants that were acquired in the Private Placement. F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. F9 · derivative.expiration_date: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm. F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseSeries I Warrants to purchase Common Stock · Derivative | 87,500 | $1.63 Strike: $1.38 | $142,861.25 |
DisclosureSEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 4 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires not disclosed F6 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series I Warrants that were acquired in the Private Placement. F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. F7 · derivative.expiration_date: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm). F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseSeries H Warrants to purchase Common Stock · Derivative | 87,500 | $1.63 Strike: $1.38 | $142,861.25 |
DisclosureSEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 3 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires not disclosed F4 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series H Warrants that were acquired in the Private Placement. F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. F5 · derivative.expiration_date: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial. F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 175,000 | $1.63 | $285,722.50 |
DisclosureSEC source: 0001493152-23-017792 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 248,534 F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement"). F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 23:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 12,037 | $3.51 | $42,288.39 |
DisclosureSEC source: 0001493152-21-030337 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 73,534 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.49 to $3.52, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| November 30, 2021 Filed Nov 30, 2021 22:53 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 18,372 | $3.55 | $65,220.60 |
DisclosureSEC source: 0001493152-21-030119 · ownership.xml · nonDerivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 61,497 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.55, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 22:53 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 3,177 | $3.55 | $11,278.35 |
DisclosureSEC source: 0001493152-21-030119 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 43,125 F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 1,200 | $3.55 | $4,260.00 |
DisclosureSEC source: 0001493152-21-030004 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 39,948 F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 21:05 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 18,328 | $3.55 | $65,064.40 |
DisclosureSEC source: 0001493152-21-029925 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 38,748 F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:34 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 1,204 | $3.55 | $4,274.20 |
DisclosureSEC source: 0001493152-21-029722 · ownership.xml · nonDerivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 20,420 F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 00:34 UTC | InspireMD, Inc. NSPR · Entity 7318 | PurchaseCommon Stock | 19,188 | $3.54 | $67,873.71 |
DisclosureSEC source: 0001493152-21-029722 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 19,216 F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 21:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 8,693 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001493152-21-025455 · ownership.xml · derivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,693 Underlying: Common Stock · 8,693 shares Expires 2031-10-13 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 21:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 26,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025455 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,320 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:57 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 79,650 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001493152-20-017126 · ownership.xml · derivative · entry 2 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,678 Underlying: Common Stock · 79,650 shares Expires 2030-08-31 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023, subject to the Reporting Person's continued service. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:57 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 238,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-017126 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,606 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023, subject to the Reporting Person's continued service. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 195,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-001458 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,999 Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:07 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 65 | $0.18 | $11.54 |
DisclosureSEC source: 0001493152-18-017322 · ownership.xml · nonDerivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 12,746 F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 18:45 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001493152-16-015749 · form4.xml · derivative · entry 1 Stuka Paul · CIK 0001528577 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2026-12-07 F1 · derivative.exercise_date: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Stuka's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.